Work

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Year: 2026

Type: article

Abstract: Incorporating prostate-specific membrane antigen (PSMA) PET/CT–derived total tumor volume with existing prediction models for overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617 improved their discriminatory ability.

Source: Radiology

DOI: 10.1148/radiol.250649

Authors: Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, Andrei Gafita, Heather H. Cheng, Jessica E. Hawley, Ruben Raychaudhuri, Hiba Khan, Rajitha Sunkara, Andrew C. Hsieh, Petros Grivas, Bruce Montgomery, Todd A. Yezefski, Peter S. Nelson, Evan Y. Yu, Michael T. Schweizer, Delphine L. Chen, Roman Gulati, Amir Iravani

Institutions: University of Washington, Fred Hutch Cancer Center, University of Iowa, Johns Hopkins University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1984635589, G402311862, G6272350879, G836263805, Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate Cancer, The Pacific Northwest Prostate Cancer SPORE

OpenAlex ID: W7143803449

FWCI: 18.37

Cites: 20

Cited by: 4

Related to: